Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Phenylephrine hydrochloride
Bausch & Lomb UK Limited
S01GA; S01GA05
Phenylephrine hydrochloride
2.5 percent weight/volume
Eye drops, solution
Product subject to prescription which may be renewed (B)
Sympathomimetics used as decongestants; phenylephrine
Marketed
1990-04-19
PACKAGE LEAFLET: INFORMATION FOR THE USER MINIMS® PHENYLEPHRINE HYDROCHLORIDE 2.5% W/V MINIMS® PHENYLEPHRINE HYDROCHLORIDE 10% W/V EYE DROPS, SOLUTION PHENYLEPHRINE HYDROCHLORIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Minims® Phenylephrine Hydrochloride eye drops are and what they are used for 2. What you need to know before you use Minims® Phenylephrine Hydrochloride eye drops 3. How to use Minims® Phenylephrine Hydrochloride eye drops 4. Possible side effects 5. How to store Minims® Phenylephrine Hydrochloride eye drops 6. Contents of the pack and other information 1. WHAT MINIMS® PHENYLEPHRINE HYDROCHLORIDE EYE DROPS ARE AND WHAT ARE THEY USED FOR Minims® Phenylephrine Hydrochloride contains a mydriatic agent. It is used to enlarge the pupil of your eye. Your doctor or eye specialist may use it to examine your eye more closely or as part of a treatment program. Minims® Phenylephrine Hydrochloride 2.5% is indicated for children, adults and the elderly. Minims® Phenylephrine Hydrochloride 10% is not indicated for children or the elderly, as this concentration is too strong. The doctor or eye specialist will use an alternative medicine in these patients. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MINIMS® PHENYLEPHRINE HYDROCHLORIDE EYE DROPS Do not use Minims® Phenylephrine Hydrochloride drops if: • you are allergic to the active substance (phenylephrine) or any of the other ingredients of this medicine (listed in section 6) • you have a heart disease • you have fast heartbeats (tachycardia) • you have high blood pressure • you have bulges in major blood vessels (aneurysms) • you have an overactive thyroid gland (hyperthyroidism) • you hav Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Minims Phenylephrine Hydrochloride 2.5% w/v eye drops, solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Phenylephrine Hydrochloride 2.5% w/v. Each unit (0.5ml) contains 12.5mg phenylephrine hydrochloride. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution. Clear, colourless, aqueous, sterile solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Phenylephrine is a directly acting sympathomimetic agent used topically in the eye as a mydriatic. It may be indicated to dilate the pupil in diagnostic or therapeutic procedures. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults, including the elderly population Apply one drop topically to each eye. If necessary, this dose may be repeated 3-4 hourly. Paediatric population Apply one drop topically to the eye. It is not usually necessary to exceed this dose. Phenylephrine 2.5%w/v eye drops may be combined with other mydriatics/cycloplegics to produce adequate mydriasis/cycloplegia. Heavily pigmented irides may require larger doses and caution should be exercised to avoid overdosage. The use in preterm and newborn infants is not recommended unless clearly necessary and only with caution because of safety concerns associated with the risk of systemic adverse reactions including transient increases in blood pressure. If treatment is medically justified the lowest possible concentration and dose should be used and instillation of more than one drop per eye must be avoided (see section 4.4). Method of administration The use of a drop of topical anaesthetic a few minutes before instillation of phenylephrine is recommended to prevent stinging. Especially in infants, children and the elderly, it is advised to minimise systemic absorption and the risk for systemic adverse reactions by compressing the lacrimal sac at the medial canthus or gently closing the eye for a few minutes after instillation. To minimise cutaneous absorption, excess fluid should be wiped aw Read the complete document